Long-term prognosis and cost-effectiveness of left ventricular assist device as bridge to transplantation: a systematic review

Seco, Michael, Zhao, Dong Fang, Byrom, Michael J., Wilson, Michael K., Vallely, Michael P., Fraser, John F. and Bannon, Paul G. (2017) Long-term prognosis and cost-effectiveness of left ventricular assist device as bridge to transplantation: a systematic review. International Journal of Cardiology, 235 22-32. doi:10.1016/j.ijcard.2017.02.137


Author Seco, Michael
Zhao, Dong Fang
Byrom, Michael J.
Wilson, Michael K.
Vallely, Michael P.
Fraser, John F.
Bannon, Paul G.
Title Long-term prognosis and cost-effectiveness of left ventricular assist device as bridge to transplantation: a systematic review
Journal name International Journal of Cardiology   Check publisher's open access policy
ISSN 1874-1754
0167-5273
Publication date 2017-05-15
Sub-type Article (original research)
DOI 10.1016/j.ijcard.2017.02.137
Open Access Status Not yet assessed
Volume 235
Start page 22
End page 32
Total pages 11
Place of publication E Park, Shannon, Clare Ireland
Publisher Elsevier Ireland
Collection year 2018
Language eng
Formatted abstract
Background: This systematic review aimed to evaluate the clinical outcomes and cost-effectiveness of left ventricular assist devices (LVADs) used as bridge to transplantation (BTT), compared to orthotopic heart transplantation (OHT) without a bridge.

Method: Systematic searches were performed in electronic databases with available data extracted from text and digitized figures. Meta-analysis of short and long-term term post-transplantation outcomes was performed with summation of cost-effectiveness analyses.

Results: Twenty studies reported clinical outcomes of 4575 patients (1083 LVAD BTT and 3492 OHT). Five studies reported cost-effectiveness data on 837 patients (339 VAD BTT and 498 OHT). There was no difference in long-term post-transplantation survival (HR 1.24, 95% CI 1.00–1.54), acute rejection (HR 1.10, 95% CI 0.93–1.30), or chronic rejection and cardiac allograft vasculopathy (HR 0.99, 95% CI 0.73–1.36). No differences were found in 30-day post-operative mortality (OR 0.91, 95% CI 0.42–2.00), stroke (OR 1.64, 95% CI 0.43–6.27), renal failure (OR 1.43, 95% CI 0.58–3.54), bleeding (OR 1.56, 95% CI 0.78–3.13), or infection (OR 2.44, 95% CI 0.81–7.38). Three of the five studies demonstrated incremental cost-effectiveness ratios below the acceptable maximum threshold. The total cost of VAD BTT ranged from $316,078 to $1,025,500, and OHT ranged from $179,051 to $802,200.

Conclusion: LVADs used as BTT did not significantly alter post-transplantation long-term survival, rejection, and post-operative morbidity. LVAD BTT may be cost-effective, particularly in medium and high-risk patients with expected prolonged waiting times, renal dysfunction, and young patients.
Keyword Bridge-to-transplantation
Heart transplantation
Left ventricular assist device
Meta-analysis
Systematic review
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 11 Apr 2017, 00:25:16 EST by Web Cron on behalf of Learning and Research Services (UQ Library)